Search Results
10
Everything
MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update
February 26, 2025 07:00 ET
|
MoonLake Immunotherapeutics AG
Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic...
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update
May 07, 2024 08:00 ET
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2024 Financial Results and Provides a Business Update Announced positive feedback from both FDA and EMA on the regulatory path for the Phase 3...